{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:24:13Z","timestamp":1794021853476,"version":"4.8.0"},"reference-count":208,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41573-019-0037-0","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T10:03:04Z","timestamp":1566900184000},"page":"827-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":525,"title":["Therapeutic strategies for hepatitis B virus infection: towards a cure"],"prefix":"10.1038","volume":"18","author":[{"given":"Gregory C.","family":"Fanning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-0083","authenticated-orcid":false,"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-0485","authenticated-orcid":false,"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,27]]},"reference":[{"key":"37_CR1","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","volume":"64","author":"M Nassal","year":"2015","unstructured":"Nassal, M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64, 1972\u20131984 (2015).","journal-title":"Gut"},{"key":"37_CR2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","volume":"479\u2013480","author":"C Seeger","year":"2015","unstructured":"Seeger, C. & Mason, W. S. Molecular biology of hepatitis B virus infection. Virology 479\u2013480, 672\u2013686 (2015).","journal-title":"Virology"},{"key":"37_CR3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005103","volume":"11","author":"SP Fletcher","year":"2015","unstructured":"Fletcher, S. P. et al. Intrahepatic transcriptional signature associated with response to interferon-\u03b1 treatment in the woodchuck model of chronic hepatitis B. PLOS Pathog. 11, e1005103 (2015).","journal-title":"PLOS Pathog."},{"key":"37_CR4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398 (2017).","journal-title":"J. Hepatol."},{"key":"37_CR5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","volume":"5","author":"J Hou","year":"2017","unstructured":"Hou, J. et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J. Clin. Transl Hepatol. 5, 297\u2013318 (2017).","journal-title":"J. Clin. Transl Hepatol."},{"key":"37_CR6","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","volume":"64","author":"D Durantel","year":"2016","unstructured":"Durantel, D. & Zoulim, F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J. Hepatol. 64, S117\u2013S131 (2016).","journal-title":"J. Hepatol."},{"key":"37_CR7","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28025","volume":"62","author":"TJ Liang","year":"2015","unstructured":"Liang, T. J. et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 62, 1893\u20131908 (2015).","journal-title":"Hepatology"},{"key":"37_CR8","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"4","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 4, 1560\u20131599 (2018).","journal-title":"Hepatology"},{"key":"37_CR9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","volume":"67","author":"AS Lok","year":"2017","unstructured":"Lok, A. S., Zoulim, F., Dusheiko, G. & Ghany, M. G. Hepatitis B cure: from discovery to regulatory approval. J. Hepatol. 67, 847\u2013861 (2017).","journal-title":"J. Hepatol."},{"key":"37_CR10","unstructured":"World Health Organization. Global hepatitis report 2017 (WHO, 2017)."},{"key":"37_CR11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","volume":"4","author":"GS Cooke","year":"2019","unstructured":"Cooke, G. S. et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology commission. Lancet Gastroenterol. Hepatol. 4, 135\u2013184 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"37_CR12","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan, H. et al. Sodium taurocholate co-transporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1, e00049 (2012).","journal-title":"eLife"},{"key":"37_CR13","volume":"92","author":"M Li","year":"2017","unstructured":"Li, M., Sohn, J. A. & Seeger, C. Distribution of hepatitis B virus nuclear DNA. J. Virol. 92, e01391-17 (2017).","journal-title":"J. Virol."},{"key":"37_CR14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","volume":"531","author":"A Decorsi\u00e8re","year":"2016","unstructured":"Decorsi\u00e8re, A. et al. Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor. Nature 531, 386\u2013389 (2016).","journal-title":"Nature"},{"key":"37_CR15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.3961490","volume":"232","author":"C Seeger","year":"1986","unstructured":"Seeger, C., Ganem, D. & Varmus, H. E. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 232, 477\u2013484 (1986).","journal-title":"Science"},{"key":"37_CR16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","volume":"65","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J. Hepatol. 65, 700\u2013710 (2016).","journal-title":"J. Hepatol."},{"key":"37_CR17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2013.06.018","volume":"59","author":"J Bayliss","year":"2013","unstructured":"Bayliss, J. et al. Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. J. Hepatol. 59, 1022\u20131028 (2013).","journal-title":"J. Hepatol."},{"key":"37_CR18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1086\/589623","volume":"198","author":"P Soussan","year":"2008","unstructured":"Soussan, P. et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J. Infect. Dis. 198, 218\u2013225 (2008).","journal-title":"J. Infect. Dis."},{"key":"37_CR19","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","volume":"126","author":"B Werle-Lapostolle","year":"2004","unstructured":"Werle-Lapostolle, B. et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750\u20131758 (2004).","journal-title":"Gastroenterology"},{"key":"37_CR20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","volume":"65","author":"A Boyd","year":"2016","unstructured":"Boyd, A. et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J. Hepatol. 65, 683\u2013691 (2016).","journal-title":"J. Hepatol."},{"key":"37_CR21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/AAC.44.1.111-122.2000","volume":"44","author":"F Le Guerhier","year":"2000","unstructured":"Le Guerhier, F. et al. Characterization of the antiviral effect of 2\u2032,3\u2032-dideoxy-2\u2032, 3\u2032-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 44, 111\u2013122 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37_CR22","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30168-9","volume":"70","author":"D Burdette","year":"2019","unstructured":"Burdette, D. et al. Evidence for the presence of infectious virus in the serum from chronic hepatitis B patients suppressed on nucleos(t)ide therapy with detectable but not quantifiable HBV DNA [abstract PS-150]. J. Hepatol. 70, e95 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","volume":"67","author":"L Allweiss","year":"2018","unstructured":"Allweiss, L. et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut 67, 542\u2013552 (2018).","journal-title":"Gut"},{"key":"37_CR24","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/JVI.01902-09","volume":"84","author":"A Schulze","year":"2010","unstructured":"Schulze, A., Schieck, A., Ni, Y., Mier, W. & Urban, S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J. Virol. 84, 1989\u20132000 (2010).","journal-title":"J. Virol."},{"key":"37_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30141-0","volume":"70","author":"H Wedemeyer","year":"2019","unstructured":"Wedemeyer, H. et al. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV\/HDV co-infection [abstract GS-13]. J. Hepatol. 70, e81 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2012.12.008","volume":"97","author":"J Lucifora","year":"2013","unstructured":"Lucifora, J., Esser, K. & Protzer, U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res. 97, 195\u2013197 (2013).","journal-title":"Antiviral Res."},{"key":"37_CR27","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","volume":"59","author":"K Watashi","year":"2014","unstructured":"Watashi, K. et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59, 1726\u20131737 (2014).","journal-title":"Hepatology"},{"key":"37_CR28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","volume":"66","author":"S Shimura","year":"2017","unstructured":"Shimura, S. et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J. Hepatol. 66, 685\u2013692 (2017).","journal-title":"J. Hepatol."},{"key":"37_CR29","first-page":"213","volume":"6","author":"D Li","year":"2017","unstructured":"Li, D. et al. A potent human neutralizing antibody Fc-dependently reduces established HBV infections. eLife 6, 213 (2017).","journal-title":"eLife"},{"key":"37_CR30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","volume":"65","author":"TY Zhang","year":"2016","unstructured":"Zhang, T. Y. et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut 65, 658\u2013671 (2016).","journal-title":"Gut"},{"key":"37_CR31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hep.23778","volume":"52","author":"AU Neumann","year":"2010","unstructured":"Neumann, A. U. et al. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology 52, 875\u2013885 (2010).","journal-title":"Hepatology"},{"key":"37_CR32","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/jhep.2002.31867","volume":"35","author":"E Galun","year":"2002","unstructured":"Galun, E. et al. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology 35, 673\u2013679 (2002).","journal-title":"Hepatology"},{"key":"37_CR33","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1128\/JVI.00430-14","volume":"88","author":"N Freitas","year":"2014","unstructured":"Freitas, N., Cunha, C., Menne, S. & Gudima, S. O. Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles. J. Virol. 88, 5742\u20135754 (2014).","journal-title":"J. Virol."},{"key":"37_CR34","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1073\/pnas.1409986111","volume":"111","author":"C K\u00f6niger","year":"2014","unstructured":"K\u00f6niger, C. et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc. Natl Acad. Sci. USA 111, 4244\u20134253 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37_CR35","volume":"13","author":"Q Long","year":"2017","unstructured":"Long, Q. et al. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. PLOS Pathog. 13, e1006784 (2017).","journal-title":"PLOS Pathog."},{"key":"37_CR36","doi-asserted-by":"crossref","first-page":"17589","DOI":"10.3390\/ijms160817589","volume":"16","author":"MB Maepa","year":"2015","unstructured":"Maepa, M. B., Roelofse, I., Abdullah, E. & Patrick, A. Progress and prospects of anti-HBV gene therapy development. Int. J. Mol. Sci. 16, 17589\u201317610 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"37_CR37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/genes9040207","volume":"9","author":"K Bloom","year":"2018","unstructured":"Bloom, K., Maepa, M. B., Ely, A. & Arbuthnot, P. Gene therapy for chronic HBV \u2014 can we eliminate cccDNA? Genes. 9, 207 (2018).","journal-title":"Genes."},{"key":"37_CR38","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/mt.2016.94","volume":"7","author":"C Seeger","year":"2016","unstructured":"Seeger, C. & Sohn, J. A. Complete spectrum of CRISPR\/Cas9-induced mutations on HBV cccDNA. Mol. Ther. 7, 1258\u20131266 (2016).","journal-title":"Mol. Ther."},{"key":"37_CR39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.01.013","volume":"70","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. A first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and HBV DNA suppression in the HBV circle mouse model through elimination of cccDNA-like molecules in the mouse liver [abstract PS-074]. J. Hepatol. 70, e48 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coviro.2018.01.009","volume":"30","author":"C Seeger","year":"2018","unstructured":"Seeger, C. Control of viral transcripts as a concept for future HBV therapies. Curr. Opin. Virol. 30, 18\u201323 (2018).","journal-title":"Curr. Opin. Virol."},{"key":"37_CR41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2015.06.023","volume":"105","author":"L Rivi\u00e8re","year":"2015","unstructured":"Rivi\u00e8re, L. et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J. Hepatol. 105, 1093\u20131102 (2015).","journal-title":"J. Hepatol."},{"key":"37_CR42","doi-asserted-by":"crossref","first-page":"19975","DOI":"10.1073\/pnas.0908365106","volume":"106","author":"L Belloni","year":"2009","unstructured":"Belloni, L. et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl Acad. Sci. USA 106, 19975\u201319979 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37_CR43","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","volume":"55","author":"J Lucifora","year":"2011","unstructured":"Lucifora, J. et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J. Hepatol. 55, 996\u20131003 (2011).","journal-title":"J. Hepatol."},{"key":"37_CR44","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.celrep.2016.08.026","volume":"16","author":"CM Murphy","year":"2016","unstructured":"Murphy, C. M. et al. Hepatitis B virus X protein promotes degradation of SMC5\/6 to enhance HBV replication. Cell Rep. 16, 2846\u20132854 (2016).","journal-title":"Cell Rep."},{"key":"37_CR45","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/hep.30491","volume":"69","author":"K Sekiba","year":"2019","unstructured":"Sekiba, K. et al. Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus. Hepatology 69, 1903\u20131915 (2019).","journal-title":"Hepatology"},{"key":"37_CR46","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","volume":"122","author":"L Belloni","year":"2012","unstructured":"Belloni, L. et al. IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J. Clin. Invest. 122, 529\u2013537 (2012).","journal-title":"J. Clin. Invest."},{"key":"37_CR47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcmgh.2018.10.010","volume":"7","author":"K Sekiba","year":"2019","unstructured":"Sekiba, K. et al. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx\u2013DDB1 interaction. Cell. Mol. Gastroenterol. Hepatol. 7, 297\u2013312 (2019).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"37_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.05.003","volume":"144","author":"CK Chong","year":"2017","unstructured":"Chong, C. K. et al. Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. Antiviral Res. 144, 1\u20137 (2017).","journal-title":"Antiviral Res."},{"key":"37_CR49","doi-asserted-by":"crossref","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","volume":"112","author":"P Tropberger","year":"2015","unstructured":"Tropberger, P. et al. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc. Natl Acad. Sci. USA 112, E5715\u2013E5724 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37_CR50","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1074\/jbc.M606774200","volume":"282","author":"D Cougot","year":"2007","unstructured":"Cougot, D. et al. The hepatitis B virus X protein functionally interacts with CREB-binding protein\/p300 in the regulation of CREB-mediated transcription. J. Biol. Chem. 282, 4277\u20134287 (2007).","journal-title":"J. Biol. Chem."},{"key":"37_CR51","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/S0168-8278(17)31855-X","volume":"66","author":"S Gilmore","year":"2017","unstructured":"Gilmore, S. et al. Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model [abstract SAT-160]. J. Hepatol. 66, S690\u2013S691 (2017).","journal-title":"J. Hepatol."},{"key":"37_CR52","doi-asserted-by":"crossref","first-page":"17589","DOI":"10.3390\/ijms160817589","volume":"16","author":"MB Maepa","year":"2015","unstructured":"Maepa, M. B., Roelofse, I., Ely, A. & Arbuthnot, P. Progress and prospects of anti-HBV gene therapy development. Int. J. Mol. Sci. 16, 17589\u201317610 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"37_CR53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","volume":"9","author":"CI Wooddell","year":"2017","unstructured":"Wooddell, C. I. et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl Med. 9, eaan0241 (2017).","journal-title":"Sci. Transl Med."},{"key":"37_CR54","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2015.11.032","volume":"64","author":"G Billioud","year":"2016","unstructured":"Billioud, G. et al. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides. J. Hepatol. 64, 781\u2013789 (2016).","journal-title":"J. Hepatol."},{"key":"37_CR55","volume":"70","author":"MF Yuen","year":"2019","unstructured":"Yuen, M. F. et al. Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg\u2009<\u2009100IUml threshold [abstract PS-080]. J. Hepatol. 70, e51 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR56","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2017.10.014","volume":"68","author":"H Mueller","year":"2018","unstructured":"Mueller, H. et al. A novel orally available small molecule that inhibits hepatitis B virus expression. J. Hepatol. 68, 412\u2013420 (2018).","journal-title":"J. Hepatol."},{"key":"37_CR57","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.antiviral.2017.11.009","volume":"149","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element. Antiviral Res. 149, 191\u2013201 (2018).","journal-title":"Antiviral Res."},{"key":"37_CR58","unstructured":"Zhang, H. et al. Safety, pharmacokinetics and anti-viral efficacy of novel core protein allosteric modifier GLS4 in patients with chronic hepatitis B: interim results from a 48 weeks phase 2a study [abstract LB-13]. Hepatology 68, 1454A\u20131455A (2018)."},{"key":"37_CR59","volume":"70","author":"E Gane","year":"2019","unstructured":"Gane, E. et al. RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients [abstract]. J. Hepatol. 70, e491 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR60","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/cb100275b","volume":"5","author":"SP Katen","year":"2010","unstructured":"Katen, S. P., Chirapu, S. R., Finn, M. G. & Zlotnick, A. Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem. Biol. 5, 1125\u20131136 (2010).","journal-title":"ACS Chem. Biol."},{"key":"37_CR61","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejmech.2017.06.062","volume":"138","author":"O Sari","year":"2017","unstructured":"Sari, O. et al. Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. Eur. J. Med. Chem. 138, 407\u2013421 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"37_CR62","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","volume":"156","author":"MF Yuen","year":"2019","unstructured":"Yuen, M. F. et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3\u2013778 in patients with chronic HBV infection. Gastroenterology 156, 1392\u20131403 (2019).","journal-title":"Gastroenterology"},{"key":"37_CR63","first-page":"47A","volume":"68","author":"F Zoulim","year":"2018","unstructured":"Zoulim, F. et al. Safety, pharmacokinetics and antiviral activity of a novel hepatitis B virus (HBV) capsid assembly modulator, JNJ-56136379, in patients with\u00a0chronic hepatitis B (CHB) [abstract]. Hepatology 68, 47A (2018).","journal-title":"Hepatology"},{"key":"37_CR64","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30925-9","volume":"70","author":"T Kakuda","year":"2019","unstructured":"Kakuda, T. et al. JNJ64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers [abstract FRI-180]. J. Hepatol. 70, e469 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR65","first-page":"A490","volume":"66","author":"T Eley","year":"2017","unstructured":"Eley, T. et al. Single dose safety, tolerability, and pharmacokinetics of AB-423 in healthy volunteers from the ongoing single and multiple ascending dose study AB-423-001 [abstract]. Hepatology 66, A490 (2017).","journal-title":"Hepatology"},{"key":"37_CR66","volume":"70","author":"X Ma","year":"2019","unstructured":"Ma, X. et al. Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-na\u00efve and treatment-suppressed chronic hepatitis B patients [abstract LBO-06]. J. Hepatol. 70, e130 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR67","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00835-18","volume":"62","author":"T Lahlali","year":"2018","unstructured":"Lahlali, T. et al. Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life-cycle. Antimicrob. Agents Chemother. 62, e00835 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37_CR68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.07.004","volume":"133","author":"A Vaillant","year":"2016","unstructured":"Vaillant, A. Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Antiviral Res. 133, 32\u201340 (2016).","journal-title":"Antiviral Res."},{"key":"37_CR69","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","volume":"12","author":"M Bazinet","year":"2017","unstructured":"Bazinet, M. et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 12, 877\u2013889 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"37_CR70","volume":"70","author":"M Bazinet","year":"2019","unstructured":"Bazinet, M. et al. Establishment of high rates of\u00a0functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: ongoing follow-up results from the REP 401 study [abstract FRI-210]. J. Hepatol. 70, e486 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","volume":"4","author":"K Zhou","year":"2019","unstructured":"Zhou, K., Contag, C., Whitaker, E. & Terrault, N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol. Hepatol. 4, 227\u2013238 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"37_CR72","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","volume":"61","author":"A Bertoletti","year":"2012","unstructured":"Bertoletti, A. & Ferrari, C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61, 1754\u20131764 (2012).","journal-title":"Gut"},{"key":"37_CR73","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.510250631","volume":"25","author":"GK Lau","year":"1997","unstructured":"Lau, G. K. et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 25, 1497\u20131501 (1997).","journal-title":"Hepatology"},{"key":"37_CR74","first-page":"246","volume":"18","author":"Y Ilan","year":"1993","unstructured":"Ilan, Y. et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 18, 246\u2013252 (1993).","journal-title":"Hepatology"},{"key":"37_CR75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","volume":"77","author":"R Thimme","year":"2003","unstructured":"Thimme, R. et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68\u201376 (2003).","journal-title":"J. Virol."},{"key":"37_CR76","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo, W. et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 27, 605\u2013611 (2009).","journal-title":"J. Clin. Oncol."},{"key":"37_CR77","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","volume":"66","author":"F Leboss\u00e9","year":"2017","unstructured":"Leboss\u00e9, F. et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J. Hepatol. 66, 897\u2013909 (2017).","journal-title":"J. Hepatol."},{"key":"37_CR78","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","volume":"101","author":"S Wieland","year":"2004","unstructured":"Wieland, S., Thimme, R., Purcell, R. H. & Chisari, F. V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl Acad. Sci. USA 101, 6669\u20136674 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37_CR79","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1053\/j.gastro.2018.01.044","volume":"154","author":"P Mutz","year":"2018","unstructured":"Mutz, P. et al. HBV bypasses the innate immune response and does not protect HCV from antiviral activity of interferon. Gastroenterology 154, 1791\u20131804 (2018).","journal-title":"Gastroenterology"},{"key":"37_CR80","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2018.01.034","volume":"154","author":"A Suslov","year":"2018","unstructured":"Suslov, A., Boldanova, T., Wang, X., Wieland, S. & Heim, M. H. Hepatitis B virus does not interfere with innate immune responses in the human liver. Gastroenterology 154, 1778\u20131790 (2018).","journal-title":"Gastroenterology"},{"key":"37_CR81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/cmi.2014.95","volume":"12","author":"AJ Gehring","year":"2015","unstructured":"Gehring, A. J. & Ann D\u2019Angelo, J. Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cell. Mol. Immunol. 12, 283\u2013291 (2015).","journal-title":"Cell. Mol. Immunol."},{"key":"37_CR82","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jhep.2016.01.028","volume":"64","author":"MK Maini","year":"2016","unstructured":"Maini, M. K. & Gehring, A. J. The role of innate immunity in the immunopathology and treatment of HBV infection. J. Hepatol. 64, S60\u2013S70 (2016).","journal-title":"J. Hepatol."},{"key":"37_CR83","unstructured":"Gehring, A. J. & Protzer, U. Targeting innate and adaptive immune responses to cure chronic HBV infection. 156, 325\u2013337 (2019)."},{"key":"37_CR84","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2004.01.011","volume":"126","author":"YF Liaw","year":"2004","unstructured":"Liaw, Y. F. et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 126, 1024\u20131029 (2004).","journal-title":"Gastroenterology"},{"key":"37_CR85","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1053\/jhep.2002.36509","volume":"36","author":"E Sagnelli","year":"2002","unstructured":"Sagnelli, E. et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 36, 1285\u20131291 (2002).","journal-title":"Hepatology"},{"key":"37_CR86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","volume":"42","author":"S Sato","year":"2015","unstructured":"Sato, S. et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 42, 123\u2013132 (2015).","journal-title":"Immunity"},{"key":"37_CR87","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora, J. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343, 1221\u20131228 (2014).","journal-title":"Science"},{"key":"37_CR88","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1128\/JVI.74.5.2255-2264.2000","volume":"74","author":"H McClary","year":"2000","unstructured":"McClary, H., Koch, R., Chisari, F. V. & Guidotti, L. G. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J. Virol. 74, 2255\u20132264 (2000).","journal-title":"J. Virol."},{"key":"37_CR89","doi-asserted-by":"crossref","first-page":"31715","DOI":"10.1074\/jbc.M113.501122","volume":"288","author":"K Watashi","year":"2013","unstructured":"Watashi, K. et al. Interleukin-1 and tumor necrosis factor-\u03b1 trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J. Biol. Chem. 288, 31715\u201331727 (2013).","journal-title":"J. Biol. Chem."},{"key":"37_CR90","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1128\/JVI.00554-07","volume":"81","author":"R Puro","year":"2007","unstructured":"Puro, R. & Schneider, R. J. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J. Virol. 81, 7351\u20137362 (2007).","journal-title":"J. Virol."},{"key":"37_CR91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2018.01.008","volume":"30","author":"A Suslov","year":"2018","unstructured":"Suslov, A., Wieland, S. & Menne, S. Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. Curr. Opin. Virol. 30, 9\u201317 (2018).","journal-title":"Curr. Opin. Virol."},{"key":"37_CR92","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fimmu.2013.00057","volume":"4","author":"MK Maini","year":"2013","unstructured":"Maini, M. K. & Peppa, D. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front. Immunol. 4, 57 (2013).","journal-title":"Front. Immunol."},{"key":"37_CR93","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jhep.2012.11.007","volume":"58","author":"R Thimme","year":"2013","unstructured":"Thimme, R. & Dandri, M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J. Hepatol. 58, 205\u2013209 (2013).","journal-title":"J. Hepatol."},{"key":"37_CR94","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/gut.2008.163600","volume":"58","author":"P Fisicaro","year":"2009","unstructured":"Fisicaro, P. et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58, 974\u2013982 (2009).","journal-title":"Gut"},{"key":"37_CR95","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/jhep.2000.19324","volume":"32","author":"GJ Webster","year":"2000","unstructured":"Webster, G. J. et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32, 1117\u20131124 (2000).","journal-title":"Hepatology"},{"key":"37_CR96","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.20121172","volume":"210","author":"D Peppa","year":"2013","unstructured":"Peppa, D. et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J. Exp. Med. 210, 99\u2013114 (2013).","journal-title":"J. Exp. Med."},{"key":"37_CR97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003784","volume":"9","author":"A Bertoletti","year":"2013","unstructured":"Bertoletti, A. & Gehring, A. J. Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLOS Pathog. 9, e1003784 (2013).","journal-title":"PLOS Pathog."},{"key":"37_CR98","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1053\/j.gastro.2013.04.028","volume":"144","author":"F Zoulim","year":"2013","unstructured":"Zoulim, F., Luangsay, S. & Durantel, D. Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B. Gastroenterology 144, 1342\u20131344 (2013).","journal-title":"Gastroenterology"},{"key":"37_CR99","volume":"12","author":"D Peppa","year":"2016","unstructured":"Peppa, D. et al. Interferon alpha induces sustained changes in NK cell responsiveness to hepatitis B viral load suppression in vivo. PLOS Pathog. 12, e1005788 (2016).","journal-title":"PLOS Pathog."},{"key":"37_CR100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","volume":"58","author":"L Micco","year":"2013","unstructured":"Micco, L. et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J. Hepatol. 58, 225\u2013233 (2013).","journal-title":"J. Hepatol."},{"key":"37_CR101","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","volume":"150","author":"Y Xia","year":"2016","unstructured":"Xia, Y. et al. Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 150, 194\u2013205 (2016).","journal-title":"Gastroenterology"},{"key":"37_CR102","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.1254082","volume":"344","author":"FV Chisari","year":"2014","unstructured":"Chisari, F. V., Mason, W. S. & Seeger, C. Comment on \u201cSpecific and non-hepatotoxic degradation of nuclear hepatitis B virus cccDNA\u201d. Science 344, 1237 (2014).","journal-title":"Science"},{"key":"37_CR103","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/hep.25875","volume":"56","author":"C Ji","year":"2012","unstructured":"Ji, C. et al. Targeted delivery of interferon-\u03b1 to hepatitis B virus-infected cells using T cell receptor-like antibodies. Hepatology 56, 2027\u20132038 (2012).","journal-title":"Hepatology"},{"key":"37_CR104","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/JVI.02008-08","volume":"83","author":"H Guo","year":"2009","unstructured":"Guo, H. et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J. Virol. 83, 847\u2013858 (2009).","journal-title":"J. Virol."},{"key":"37_CR105","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1128\/AAC.04321-14","volume":"59","author":"F Guo","year":"2015","unstructured":"Guo, F. et al. STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob. Agents Chemother. 59, 1273\u20131281 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"37_CR106","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","volume":"144","author":"RE Lanford","year":"2013","unstructured":"Lanford, R. E. et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144, 1508\u20131517 (2013).","journal-title":"Gastroenterology"},{"key":"37_CR107","first-page":"229A","volume":"68","author":"D Colledge","year":"2018","unstructured":"Colledge, D. et al. Inarigivir is a novel selective inhibitor of the HBV replicase complex in vitro [abstract]. Hepatology 68, 229A (2018).","journal-title":"Hepatology"},{"key":"37_CR108","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S0618-8278(19)30084-2","volume":"70","author":"MF Yuen","year":"2019","unstructured":"Yuen, M. F. et al. Ascending dose cohort study of\u00a0inarigivir \u2013 a novel RIG I agonist in chronic HBV patients: final results of the ACHIEVE trial [abstract GS-12]. J. Hepatol. 70, e47\u2013e48 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR109","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","volume":"62","author":"S Menne","year":"2015","unstructured":"Menne, S. et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J. Hepatol. 62, 1237\u20131245 (2015).","journal-title":"J. Hepatol."},{"key":"37_CR110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","volume":"63","author":"EJ Gane","year":"2015","unstructured":"Gane, E. J. et al. The oral Toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J. Hepatol. 63, 320\u2013328 (2015).","journal-title":"J. Hepatol."},{"key":"37_CR111","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","volume":"154","author":"C Boni","year":"2018","unstructured":"Boni, C. et al. TLR7 agonist increases responses of\u00a0hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Gastroenterology 154, 1764\u20131777 (2018).","journal-title":"Gastroenterology"},{"key":"37_CR112","volume":"10","author":"J Jo","year":"2014","unstructured":"Jo, J. et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLOS Pathog. 10, e1004210 (2014).","journal-title":"PLOS Pathog."},{"key":"37_CR113","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.4049\/jimmunol.1203218","volume":"190","author":"XZ Tang","year":"2013","unstructured":"Tang, X. Z. et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J. Immunol. 190, 3142\u20133152 (2013).","journal-title":"J. Immunol."},{"key":"37_CR114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003208","volume":"9","author":"A Schurich","year":"2013","unstructured":"Schurich, A. et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLOS Pathog. 9, e1003208 (2013).","journal-title":"PLOS Pathog."},{"key":"37_CR115","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni, C. et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215\u20134225 (2007).","journal-title":"J. Virol."},{"key":"37_CR116","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","volume":"138","author":"P Fisicaro","year":"2010","unstructured":"Fisicaro, P. et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138, 682\u2013693 (2010).","journal-title":"Gastroenterology"},{"key":"37_CR117","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1172\/JCI121957","volume":"128","author":"L Salimzadeh","year":"2018","unstructured":"Salimzadeh, L. et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Invest. 128, 4573\u20134587 (2018).","journal-title":"J. Clin. Invest."},{"key":"37_CR118","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1172\/JCI121960","volume":"128","author":"AR Burton","year":"2018","unstructured":"Burton, A. R. et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J. Clin. Invest. 128, 4588\u20134603 (2018).","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 1","key":"37_CR119","first-page":"23A","volume":"66","author":"D Verdon","year":"2017","unstructured":"Verdon, D. et al. Immunological assessment of HBeAg-negative chronic hepatitis B patient responses following anti-PD-1 treatment [abstract 41]. Hepatology 66 (Suppl. 1), 23A (2017).","journal-title":"Hepatology"},{"key":"37_CR120","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0264-410X(00)00461-8","volume":"19","author":"ML Michel","year":"2001","unstructured":"Michel, M. L., Pol, S., Brechot, C. & Tiollais, P. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 19, 2395\u20132399 (2001).","journal-title":"Vaccine"},{"key":"37_CR121","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/hep.20408","volume":"40","author":"M Mancini-Bourgine","year":"2004","unstructured":"Mancini-Bourgine, M. et al. Induction or expansion of T cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40, 874\u2013882 (2004).","journal-title":"Hepatology"},{"key":"37_CR122","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","volume":"25","author":"P Vandepapeli\u00e8re","year":"2007","unstructured":"Vandepapeli\u00e8re, P. et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine. Vaccine 25, 8585\u20138597 (2007).","journal-title":"Vaccine"},{"key":"37_CR123","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","volume":"59","author":"DZ Xu","year":"2013","unstructured":"Xu, D. Z. et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J. Hepatol. 59, 450\u2013456 (2013).","journal-title":"J. Hepatol."},{"key":"37_CR124","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","volume":"22","author":"O Godon","year":"2013","unstructured":"Godon, O. et al. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol. Ther. 22, 675\u2013684 (2013).","journal-title":"Mol. Ther."},{"key":"37_CR125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","volume":"65","author":"AS Lok","year":"2016","unstructured":"Lok, A. S. et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J. Hepatol. 65, 509\u2013516 (2016).","journal-title":"J. Hepatol."},{"key":"37_CR126","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","volume":"157","author":"C Boni","year":"2019","unstructured":"Boni, C. et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology 157, 227\u2013241 (2019).","journal-title":"Gastroenterology"},{"key":"37_CR127","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu, J. et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLOS Pathog. 10, e1003856 (2014).","journal-title":"PLOS Pathog."},{"key":"37_CR128","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.201141852","volume":"42","author":"W Wu","year":"2012","unstructured":"Wu, W. et al. Blockade of Tim-3 signaling restores the virus-specific CD8+ T cell response in patients with chronic hepatitis B. Eur. J. Immunol. 42, 1180\u20131191 (2012).","journal-title":"Eur. J. Immunol."},{"key":"37_CR129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1084\/jem.20131333","volume":"211","author":"PD Kurktschiev","year":"2014","unstructured":"Kurktschiev, P. D. et al. Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J. Exp. Med. 211, 167 (2014).","journal-title":"J. Exp. Med."},{"key":"37_CR130","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","volume":"61","author":"B Bengsch","year":"2014","unstructured":"Bengsch, B., Martin, B. & Thimme, R. Restoration of\u00a0HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J. Hepatol. 61, 1212\u20131219 (2014).","journal-title":"J. Hepatol."},{"key":"37_CR131","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.celrep.2016.06.078","volume":"16","author":"A Schurich","year":"2016","unstructured":"Schurich, A. et al. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep. 16, 1243\u20131252 (2016).","journal-title":"Cell Rep."},{"key":"37_CR132","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.4275","volume":"23","author":"P Fisicaro","year":"2017","unstructured":"Fisicaro, P. et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat. Med. 23, 327\u2013336 (2017).","journal-title":"Nat. Med."},{"key":"37_CR133","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1172\/JCI93024","volume":"127","author":"J Kah","year":"2017","unstructured":"Kah, J. et al. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J. Clin. Invest. 127, 3177\u20133188 (2017).","journal-title":"J. Clin. Invest."},{"key":"37_CR134","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.gastro.2018.03.027","volume":"155","author":"S Koh","year":"2018","unstructured":"Koh, S. et al. Non-lytic lymphocytes engineered to express virus-specific T cell receptors limit HBV infection by activating APOBEC3. Gastroenterology 155, 180\u2013193 (2018).","journal-title":"Gastroenterology"},{"key":"37_CR135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","volume":"134","author":"F Bohne","year":"2008","unstructured":"Bohne, F. et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134, 239\u2013247 (2008).","journal-title":"Gastroenterology"},{"key":"37_CR136","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","volume":"55","author":"AJ Gehring","year":"2011","unstructured":"Gehring, A. J. et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J. Hepatol. 55, 103\u2013110 (2011).","journal-title":"J. Hepatol."},{"key":"37_CR137","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","volume":"145","author":"K Krebs","year":"2013","unstructured":"Krebs, K. et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145, 456\u2013465 (2013).","journal-title":"Gastroenterology"},{"key":"37_CR138","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","volume":"62","author":"W Qasim","year":"2015","unstructured":"Qasim, W. et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J. Hepatol. 62, 486\u2013491 (2015).","journal-title":"J. Hepatol."},{"key":"37_CR139","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/cgt.2014.78","volume":"22","author":"AD Kaiser","year":"2015","unstructured":"Kaiser, A. D. et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 22, 72\u201378 (2015).","journal-title":"Cancer Gene Ther."},{"key":"37_CR140","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1128\/JVI.01990-10","volume":"85","author":"KS Sastry","year":"2011","unstructured":"Sastry, K. S. et al. Targeting hepatitis B virus-infected cells with a T cell receptor-like antibody. J. Virol. 85, 1935\u20131942 (2011).","journal-title":"J. Virol."},{"key":"37_CR141","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.molimm.2015.01.024","volume":"67","author":"J Oates","year":"2015","unstructured":"Oates, J., Hassan, N. J. & Jakobsen, B. K. ImmTACs for targeted cancer therapy: why, what, how, and which. Mol. Immunol. 67, 67\u201374 (2015).","journal-title":"Mol. Immunol."},{"key":"37_CR142","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/mt.2016.114","volume":"24","author":"H Yang","year":"2016","unstructured":"Yang, H. et al. Elimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune-mobilizing T cell receptors. Mol. Ther. 24, 1913\u20131925 (2016).","journal-title":"Mol. Ther."},{"key":"37_CR143","volume":"9","author":"F Liu","year":"2013","unstructured":"Liu, F. et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLOS Pathog. 9, e1003613 (2013).","journal-title":"PLOS Pathog."},{"key":"37_CR144","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2008.12.021","volume":"50","author":"KA Kim","year":"2009","unstructured":"Kim, K. A. et al. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV\/HIV infection. J. Hepatol. 50, 705\u2013711 (2009).","journal-title":"J. Hepatol."},{"key":"37_CR145","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.25730","volume":"11","author":"SP Fletcher","year":"2012","unstructured":"Fletcher, S. P. et al. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology 11, 820\u2013830 (2012).","journal-title":"Hepatology"},{"key":"37_CR146","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.virusres.2009.12.003","volume":"148","author":"B Koeberlein","year":"2010","unstructured":"Koeberlein, B. et al. Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver. Virus Res. 148, 51\u201359 (2010).","journal-title":"Virus Res."},{"key":"37_CR147","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2017.04.023","volume":"67","author":"A Tan-Garcia","year":"2017","unstructured":"Tan-Garcia, A. et al. Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease. J. Hepatol. 67, 490\u2013500 (2017).","journal-title":"J. Hepatol."},{"key":"37_CR148","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ni.3399","volume":"17","author":"M Beyer","year":"2016","unstructured":"Beyer, M. et al. Tumor-necrosis factor impairs CD4+ T cell\u2013mediated immunological control in chronic viral infection. Nat. Immunol. 17, 593\u2013603 (2016).","journal-title":"Nat. Immunol."},{"key":"37_CR149","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1084\/jem.20072076","volume":"205","author":"A Das","year":"2008","unstructured":"Das, A. et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J. Exp. Med. 205, 2111\u20132124 (2008).","journal-title":"J. Exp. Med."},{"key":"37_CR150","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.gastro.2012.03.041","volume":"143","author":"E Sandalova","year":"2012","unstructured":"Sandalova, E. et al. Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology 143, 78\u201387 (2012).","journal-title":"Gastroenterology"},{"key":"37_CR151","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nm.3856","volume":"21","author":"LJ Pallett","year":"2015","unstructured":"Pallett, L. J. et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat. Med. 21, 591\u2013600 (2015).","journal-title":"Nat. Med."},{"key":"37_CR152","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","volume":"161","author":"LG Guidotti","year":"2015","unstructured":"Guidotti, L. G. et al. Immunosurveillance of the liver by intravascular effector CD8+ T cells. Cell 161, 486\u2013500 (2015).","journal-title":"Cell"},{"key":"37_CR153","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","volume":"126","author":"ML Op den Brouw","year":"2009","unstructured":"Op den Brouw, M. L. et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 126, 280\u2013289 (2009).","journal-title":"Immunology"},{"key":"37_CR154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015324","volume":"6","author":"AM Woltman","year":"2011","unstructured":"Woltman, A. M. et al. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLOS ONE 6, e15324 (2011).","journal-title":"PLOS ONE"},{"key":"37_CR155","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.molimm.2009.04.031","volume":"46","author":"Y Xu","year":"2009","unstructured":"Xu, Y. et al. HBsAg inhibits TLR9-mediated activation and IFN-\u03b1 production in plasmacytoid dendritic cells. Mol. Immunol. 46, 2640\u20132646 (2009).","journal-title":"Mol. Immunol."},{"key":"37_CR156","volume":"7","author":"B Shi","year":"2017","unstructured":"Shi, B. et al. HBsAg inhibits IFN-\u03b1 production in plasmacytoid dendritic cells through TNF-\u03b1 and IL-10 induction in monocytes. PLOS ONE 7, e44900 (2017).","journal-title":"PLOS ONE"},{"key":"37_CR157","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/hep.21482","volume":"45","author":"K Visvanathan","year":"2006","unstructured":"Visvanathan, K. et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the pre-core protein. Hepatology 45, 102\u2013110 (2006).","journal-title":"Hepatology"},{"key":"37_CR158","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.22751","volume":"49","author":"J Wu","year":"2009","unstructured":"Wu, J. et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49, 1132\u20131140 (2009).","journal-title":"Hepatology"},{"key":"37_CR159","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2012.08.046","volume":"143","author":"J Martinet","year":"2012","unstructured":"Martinet, J. et al. Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 143, 1586\u20131596 (2012).","journal-title":"Gastroenterology"},{"key":"37_CR160","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1172\/JCI66043","volume":"123","author":"AJ Gehring","year":"2013","unstructured":"Gehring, A. J. et al. Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J. Clin. Invest. 123, 3766\u20133776 (2013).","journal-title":"J. Clin. Invest."},{"key":"37_CR161","volume":"6","author":"BB Andrade","year":"2011","unstructured":"Andrade, B. B. et al. Hepatitis B infection is associated with asymptomatic malaria in the Brazilian Amazon. PLOS ONE 6, e19841 (2011).","journal-title":"PLOS ONE"},{"key":"37_CR162","volume":"6","author":"M Hong","year":"2015","unstructured":"Hong, M. et al. Trained immunity in newborn infants of HBV-infected mothers. Nat. Commun. 6, 6588 (2015).","journal-title":"Nat. Commun."},{"key":"37_CR163","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1073\/pnas.87.17.6599","volume":"87","author":"DR Milich","year":"1990","unstructured":"Milich, D. R. et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl Acad. Sci. USA 87, 6599\u20136603 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37_CR164","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","volume":"150","author":"JJ Park","year":"2015","unstructured":"Park, J. J. et al. Hepatitis B virus\u2014specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology 150, 684\u2013695 (2015).","journal-title":"Gastroenterology"},{"key":"37_CR165","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","volume":"68","author":"A Schuch","year":"2019","unstructured":"Schuch, A. et al. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut 68, 905\u2013915 (2019).","journal-title":"Gut"},{"key":"37_CR166","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gutjnl-2018-316644","volume":"68","author":"RC Hoogeveen","year":"2019","unstructured":"Hoogeveen, R. C. et al. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut 68, 893\u2013904 (2019).","journal-title":"Gut"},{"key":"37_CR167","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/cmi.2014.79","volume":"12","author":"A Bertoletti","year":"2015","unstructured":"Bertoletti, A. & Kennedy, P. T. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell. Mol. Immunol. 12, 258\u2013263 (2015).","journal-title":"Cell. Mol. Immunol."},{"key":"37_CR168","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coviro.2018.03.006","volume":"30","author":"GE Dolman","year":"2018","unstructured":"Dolman, G. E., Koffas, A., Mason, W. S. & Kennedy, P. T. Why, who and when to start treatment for chronic hepatitis B virus infection. Curr. Opin. Virol. 30, 39\u201347 (2018).","journal-title":"Curr. Opin. Virol."},{"key":"37_CR169","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill, P. A. et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545\u2013558 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"37_CR170","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.gastro.2018.11.062","volume":"156","author":"RT Anderson","year":"2019","unstructured":"Anderson, R. T. et al. Challenges, considerations and principles to guide trials of combination therapies for chronic HBV infection. Gastroenterology 156, 529\u2013533 (2019).","journal-title":"Gastroenterology"},{"key":"37_CR171","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gutjnl-2011-300937","volume":"61","author":"F Zoulim","year":"2012","unstructured":"Zoulim, F. & Mason, W. S. Reasons to consider earlier treatment of chronic HBV infections. Gut 61, 333\u2013336 (2012).","journal-title":"Gut"},{"key":"37_CR172","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30916-8","volume":"70","author":"D Armas","year":"2019","unstructured":"Armas, D. et al. A phase I single ascending dose study of CRV431 [abstract]. J. Hepatol. 70, e464 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR173","first-page":"LB17","volume":"66","author":"K Agarwal","year":"2017","unstructured":"Agarwal, K. et al. Bi-weekly dosing of ARB-1467 LNP siRNA in HBeAg negative, virally suppressed patients with chronic HBV infection leads to deeper declines in HBsAg and potential association with IL28b [abstract]. Hepatology 66, LB17 (2017).","journal-title":"Hepatology"},{"key":"37_CR174","first-page":"A490","volume":"66","author":"K Han","year":"2017","unstructured":"Han, K. et al. Safety, tolerability and pharmacokinetics of GSK3389404, an antisense oligonucleotide for the treatment of chronic hepatitis B (CHB) infection: a randomized, double-blind, placebo-controlled, dose-escalation, first time in human study [abstract]. Hepatology 66, A490 (2017).","journal-title":"Hepatology"},{"key":"37_CR175","unstructured":"Arbutus Biopharma. Press release: Arbutus reports first quarter 2019 financial results and provides corporate update. Arbutus Biopharma \nhttps:\/\/investor.arbutusbio.com\/news-releases\/news-release-details\/arbutus-reports-first-quarter-2019-financial-results-and\n\n (2019)."},{"key":"37_CR176","doi-asserted-by":"crossref","first-page":"LB","DOI":"10.1002\/hep.30126","volume":"68","author":"E Gane","year":"2018","unstructured":"Gane, E. et al. TLR7 agonist RO7020531 triggers immune activation after multiple doses in chronic hepatitis B patients [abstract]. Hepatology 68, LB\u201333 (2018).","journal-title":"Hepatology"},{"key":"37_CR177","first-page":"233A","volume":"68","author":"M Reyes","year":"2018","unstructured":"Reyes, M. et al. First in human study of GS-9688, an oral Toll-like receptor 8 (TLR8) agonist, in healthy volunteers: assessment of safety, tolerability, pharmacokinetics, pharmacodynamics and food effect [abstract]. Hepatology 68, 233A (2018).","journal-title":"Hepatology"},{"key":"37_CR178","first-page":"252A","volume":"68","author":"C Fournier","year":"2018","unstructured":"Fournier, C. et al. Safety and immunogenicity of single and multiple injections of the therapeutic vaccine TG1050 in NUC-suppressed chronic hepatitis B (CHB) patients: unblinded analysis of a double-blind, placebo-controlled phase 1b study [abstract]. Hepatology 68, 252A (2018).","journal-title":"Hepatology"},{"key":"37_CR179","volume":"70","author":"Y Hu","year":"2019","unstructured":"Hu, Y. et al. A phase 1 clinical trial of therapeutic vaccine t101 in chronic hepatitis b patients: a randomized, double-blind, placebo controlled, single and multiple injections, dose escalation study [abstract]. J. Hepatol. 70, e153 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR180","volume":"70","author":"YS Lim","year":"2019","unstructured":"Lim, Y. S. et al. A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection [abstract]. J. Hepatol. 70, e50 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR181","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","volume":"60","author":"FS Wang","year":"2014","unstructured":"Wang, F. S., Fan, J. G., Zhang, Z., Gao, B. & Wang, H. Y. The global burden of liver disease: the major impact of China. Hepatology 60, 2099\u20132108 (2014).","journal-title":"Hepatology"},{"key":"37_CR182","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2010","unstructured":"Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. Lancet 380, 2095\u20132128 (2010).","journal-title":"Lancet"},{"key":"37_CR183","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0928-4346(96)82012-3","volume":"5","author":"G-L Xia","year":"1996","unstructured":"Xia, G. \u2011L. et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int. Hepatol. Comm. 5, 62\u201373 (1996).","journal-title":"Int. Hepatol. Comm."},{"key":"37_CR184","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1086\/599332","volume":"200","author":"X Liang","year":"2009","unstructured":"Liang, X. et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992\u20132005 in China. J. Infect. Dis. 200, 39\u201347 (2009).","journal-title":"J. Infect. Dis."},{"key":"37_CR185","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott, J. J., Stevens, G. A., Groeger, J. & Wiersma, S. T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212\u20132219 (2012).","journal-title":"Vaccine"},{"key":"37_CR186","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/genes9100495","volume":"9","author":"S Velkov","year":"2018","unstructured":"Velkov, S., Ott, J. J., Protzer, U. & Michler, T. The global hepatitis B virus genotype distribution approximated from available genotyping data. Genes 9, 495 (2018).","journal-title":"Genes"},{"key":"37_CR187","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","volume":"67","author":"N Rajoriya","year":"2017","unstructured":"Rajoriya, N., Combet, C., Zoulim, F. & Janssen, H. L. A. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach? J. Hepatol. 67, 1281\u20131297 (2017).","journal-title":"J. Hepatol."},{"key":"37_CR188","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-0037-1606212","volume":"37","author":"B Testoni","year":"2017","unstructured":"Testoni, B., Levrero, M. & Zoulim, F. Challenges to a cure for HBV infection. Semin. Liver Dis. 37, 231\u2013242 (2017).","journal-title":"Semin. Liver Dis."},{"key":"37_CR189","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","volume":"66","author":"M Cornberg","year":"2017","unstructured":"Cornberg, M. et al. The role of quantitative hepatitis B surface antigen revisited. J. Hepatol. 66, 398\u2013411 (2017).","journal-title":"J. Hepatol."},{"key":"37_CR190","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.30082","volume":"68","author":"EK Butler","year":"2018","unstructured":"Butler, E. K. et al. Hepatitis B virus serum DNA and RNA Levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology 68, 2106\u20132117 (2018).","journal-title":"Hepatology"},{"key":"37_CR191","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","volume":"69","author":"S Liu","year":"2019","unstructured":"Liu, S. et al. RNA: a new potential biomarker for chronic hepatitis B virus infection. Hepatology 69, 1816\u20131827 (2019).","journal-title":"Hepatology"},{"key":"37_CR192","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/infdis\/jiv572","volume":"213","author":"M Honda","year":"2016","unstructured":"Honda, M. et al. Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J. Infect. Dis. 213, 1096\u20131106 (2016).","journal-title":"J. Infect. Dis."},{"key":"37_CR193","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","volume":"70","author":"B Testoni","year":"2019","unstructured":"Testoni, B. et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J. Hepatol. 70, 615\u2013625 (2019).","journal-title":"J. Hepatol."},{"key":"37_CR194","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/viro.1996.0661","volume":"226","author":"AR Jilbert","year":"1996","unstructured":"Jilbert, A. R., Miller, D. S., Scougall, C. A., Turnbull, H. & Burrell, C. J. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one\u00a0virus DNA genome is infectious in neonatal ducks. Virology 226, 338\u2013345 (1996).","journal-title":"Virology"},{"key":"37_CR195","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/hep.28957","volume":"66","author":"X Chen","year":"2017","unstructured":"Chen, X. et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. Hepatology 66, 1739\u20131749 (2017).","journal-title":"Hepatology"},{"key":"37_CR196","volume":"9","author":"B Liao","year":"2014","unstructured":"Liao, B. et al. Epidemiological, clinical and histological characteristics of HBV\/HDV co-infection: a retrospective cross-sectional study in Guangdong. PLOS ONE 9, e115888 (2014).","journal-title":"PLOS ONE"},{"key":"37_CR197","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","volume":"13","author":"FA Lempp","year":"2016","unstructured":"Lempp, F. A., Ni, Y. & Urban, S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat. Rev. Gastroenterol. Hepatol. 13, 580\u2013589 (2016).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"37_CR198","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","volume":"67","author":"C Yurdaydin","year":"2018","unstructured":"Yurdaydin, C. et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology 67, 1224\u20131236 (2018).","journal-title":"Hepatology"},{"key":"37_CR199","unstructured":"US Food and Drug Administration. Codevelopment of two or more new investigational drugs for use in combination. FDA \nhttps:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/codevelopment-two-or-more-new-investigational-drugs-use-combination\n\n (2013)."},{"key":"37_CR200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.29112","volume":"66","author":"FA Lempp","year":"2017","unstructured":"Lempp, F. A. et al. Sodium taurocholate co-transporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes. Hepatology 66, 703\u2013716 (2017).","journal-title":"Hepatology"},{"key":"37_CR201","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bpg.2017.04.014","volume":"31","author":"M Dandri","year":"2017","unstructured":"Dandri, M. & Petersen, J. Animal models of HBV infection. Best Pract. Res. Clin. Gastroenterol. 31, 273\u2013279 (2017).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"37_CR202","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119820","volume":"10","author":"H Strick-Marchand","year":"2015","unstructured":"Strick-Marchand, H. et al. A novel mouse model for stable engraftment of a human immune system and human hepatocytes. PLOS ONE 10, e0119820 (2015).","journal-title":"PLOS ONE"},{"key":"37_CR203","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hep.510310128","volume":"31","author":"PJ Cote","year":"2000","unstructured":"Cote, P. J. et al. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 31, 190\u2013200 (2000).","journal-title":"Hepatology"},{"key":"37_CR204","volume":"8","author":"BJ Burwitz","year":"2017","unstructured":"Burwitz, B. J. et al. Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques. Nat. Commun. 8, 2146 (2017).","journal-title":"Nat. Commun."},{"key":"37_CR205","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4049\/jimmunol.177.1.739","volume":"177","author":"D Xu","year":"2006","unstructured":"Xu, D. et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177, 739\u2013747 (2006).","journal-title":"J. Immunol."},{"key":"37_CR206","doi-asserted-by":"crossref","first-page":"J21","DOI":"10.1016\/j.vaccine.2013.08.012","volume":"31","author":"X Liang","year":"2013","unstructured":"Liang, X. et al. Reprint of: Epidemiological serosurvey of hepatitis B in China \u2014 declining HBV prevalence due to hepatitis B vaccination. Vaccine 31, J21\u2013J28 (2013).","journal-title":"Vaccine"},{"key":"37_CR207","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1473-3099(15)00218-2","volume":"16","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21\u201349 years in rural China: a population-based, cross-sectional study. Lancet Infect. Dis. 16, 80\u201386 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"37_CR208","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3201\/eid2305.161477","volume":"23","author":"F Cui","year":"2017","unstructured":"Cui, F. et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerging Infect. Dis. 23, 765 (2017).","journal-title":"Emerging Infect. Dis."}],"updated-by":[{"DOI":"10.1038\/s41573-019-0057-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000}}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41573-019-0037-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41573-019-0037-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41573-019-0037-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:44:55Z","timestamp":1684619095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-019-0037-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,27]]},"references-count":208,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1038\/s41573-019-0037-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41573-019-0057-9","asserted-by":"object"}]},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,27]]},"assertion":[{"value":"9 July 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.C.F. is an employee of Janssen Pharmaceuticals. A.B. participates in advisory boards\/consultancy on hepatitis B virus (HBV) immune therapy for Gilead, Janssen, Vir, Jiangsu Simcere Pharmaceutical and Humabs BioMed; is the scientific founder of Lion TCR Pte. Ltd.; is an advisor for Arbutus, Assembly, Gilead, Janssen, Myr Pharma, Roche, Transgene and Vir Biotech; and has received research grants from Evotec and Roche. F.Z. participates in advisory boards on HBV for AbbVie, Aligos, Gilead, Janssen, Myr Pharma, Spring Bank, Roche, Transgene and Vir Biotech; and has received research grants from Evotec and Roche. J.H. participates in advisory boards\/consultancy for AbbVie, Arbutus, Bristol\u2013Myers Squibb, Gilead Sciences, Johnson & Johnson and Roche, and has received grants from Bristol\u2013Myers Squibb and Johnson & Johnson.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}